Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The cumulative incidence of hepatocellular carcinoma at ...

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D ...

− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected – − Progression into clinical studies ...

Huahei Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...

-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...